E

NEON shines the light on Neoantigen targeted Cancer Immunotherapy

Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...

August 11, 2016
E

Can we safely revisit the IGF pathway with combinations?

Lilly and Boehringer Ingelheim have announced a clinical trial collaboration in metastatic breast cancer with the CDK4/6 inhibitor, abemaciclib, and the IGF antibody, BI 836845.

July 14, 2016
E

The changing face of the SCCHN landscape

A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before

July 12, 2016
E

Can epigenetics play a role in immunomodulation?

Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?

July 7, 2016
E

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016
E

The impact of niraparib on the ovarian cancer landscape

How will niraparib impact the ovarian cancer market?

June 30, 2016
E

The potential downside of cancer immunotherapy

We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.

June 27, 2016
E

How to turn a cold tumour into a hot one

Can we turn a cold tumour into a hot one where some patients can respond to therapy?

June 23, 2016
E

Checkpoint blockade in MSI High cancers

Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers

June 22, 2016
E

Immunoscore validated as an important biomarker for colon cancer

An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.

June 20, 2016
E

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016
E

Beyond PD-L1 Immunotherapy Biomarkers

Can we find and use several biomarkers to triangulate responders and non-responders?

June 16, 2016
E

Urothelial Cancer Immunotherapy is a Competitive Landscape

A look at the increasingly competitive metastatic urothelial carcinoma landscape

June 15, 2016
E

Contemplations on ASCO Lung Cancer Data with Dr Stephen Liu

What to make of the various combination trials presented at ASCO 2016?

June 13, 2016
E

5 Important and Emerging Trends from ASCO 2016

A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?

June 9, 2016
E

BMS Ipilimumab prostate cancer immunotherapy trial fails but where is the data?

Prior to chemotherapy men with advanced prostate cancer did not live longer if they received ipilimumab compared to just receiving placebo. The phase 3 trial was a failure.

June 5, 2016
E

ASCO 2016 Monday Blog #ASCO16

Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago

June 6, 2016
E

ASCO 2016 Sunday Blog #ASCO16

Top-line commentary from Sunday at ASCO 2016 annual meeting.

June 5, 2016
E
Chicago River

ASCO 2016 Chicago Saturday Blog #ASCO16

Top-line commentary from Saturday at ASCO 2016 annual meeting.

June 4, 2016
E

ASCO 2016 – Top 10 Immunotherapy Abstracts Worth Checking Out

What are our Top Ten immunotherapy abstracts of note at ASCO 2016?

June 2, 2016
E

ASCO 2016 Preview on Targeted Therapies

The poster childs for targeted therapies have been surprising - CML and lung cancer -- what's new here at #ASCO16?

June 1, 2016
E

ASCO 2016 Preview 1 – Novel Combination Approaches

A look at 10 ASCO 2016 abstracts with novel combination data - what's going to make an impact?

May 31, 2016